Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ILMN | ILLUMINA, INC. | 2025-10-16 21:04:35 | 95.38 | -0.53 | -0.55 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMN | 0001110803 | ILLUMINA, INC. | US4523271090 | SQ95QG8SR5Q56LSNF682 | 330804655 | Nasdaq | 3826 | Laboratory Analytical Instruments | 1228 | DE | 5200 ILLUMINA WAY | SAN DIEGO | CA | 92122 | UNITED STATES | US | 8582024500 | 5200 ILLUMINA WAY, SAN DIEGO, CA, 92122 | 5200 ILLUMINA WAY, SAN DIEGO, CA, 92122 | ILLUMINA INC | Biotechnology | 1998 | Jacob Thaysen | 8,970 | https://www.illumina.com/ | 14,700,000,000 | 200,000,000 | 153,700,000 | Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries. | 2025-10-10 19:39:49 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 14,700,000,000 | -11,800,000,000 | -44.5283 | 158,400,000 | -500,000 | -0.3147 |
| 2023 | 26,500,000,000 | 400,000,000 | 1.5326 | 158,900,000 | 900,000 | 0.5696 |
| 2022 | 26,100,000,000 | -34,100,000,000 | -56.6445 | 158,000,000 | 1,000,000 | 0.6369 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Steve Barnard | Chief Technology Officer | 2024 | 593,269 | 0 | 3,046,027 | 358,963 | 22,677 | 4,020,936 |
| Everett Cunningham | Chief Commercial Officer | 2024 | 350,000 | 500,000 | 8,718,496 | 219,131 | 286,191 | 10,073,818 |
| Jacob Thaysen | Chief Executive Officer | 2024 | 1,000,000 | 0 | 12,306,550 | 1,162,500 | 333,874 | 14,802,924 |
| Ankur Dhingra | Chief Financial Officer | 2024 | 450,000 | 500,000 | 4,011,041 | 279,581 | 615,465 | 5,856,087 |
| Charles Dadswell | Secretary, General Counsel | 2024 | 614,615 | 0 | 3,514,790 | 371,801 | 15,997 | 4,517,203 |
| Fiscal Year | Employee Count |
|---|---|
| 2019 | 7,700 |
| 2018 | 7,300 |
| 2017 | 5,500 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 4,372,000,000 | 4,504,000,000 | 4,584,000,000 |
| Cost Of Revenue | 1,511,000,000 | 1,760,000,000 | 1,612,000,000 |
| Gross Profit | 2,861,000,000 | 2,744,000,000 | 2,972,000,000 |
| Research And Development Expenses | 1,169,000,000 | 1,354,000,000 | 1,321,000,000 |
| General And Administrative Expenses | 1,092,000,000 | 1,612,000,000 | 1,297,000,000 |
| Operating Expenses | 3,694,000,000 | 3,813,000,000 | 7,151,000,000 |
| Operating Income | -833,000,000 | -1,069,000,000 | -4,179,000,000 |
| Net Income | -1,223,000,000 | -1,161,000,000 | -4,404,000,000 |
| Earnings Per Share Basic | -7.69 | -7.34 | -28 |
| Earnings Per Share Diluted | -7.69 | -7.34 | -28 |
| Weighted Average Shares Outstanding Basic | 159,000,000 | 158,000,000 | 157,000,000 |
| Weighted Average Shares Outstanding Diluted | 159,000,000 | 158,000,000 | 157,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 1,127,000,000 | 1,048,000,000 | 2,011,000,000 |
| Marketable Securities Current | 93,000,000 | 6,000,000 | 26,000,000 |
| Accounts Receivable | 735,000,000 | 734,000,000 | 671,000,000 |
| Inventories | 547,000,000 | 587,000,000 | 568,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 2,746,000,000 | 2,609,000,000 | 3,561,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 815,000,000 | 1,007,000,000 | 1,091,000,000 |
| Other Assets Non Current | 348,000,000 | 413,000,000 | 423,000,000 |
| Total Assets Non Current | 1,234,000,000 | 7,502,000,000 | 8,691,000,000 |
| Total Assets | 6,303,000,000 | 10,111,000,000 | 12,252,000,000 |
| Accounts Payable | 221,000,000 | 245,000,000 | 293,000,000 |
| Deferred Revenue | 260,000,000 | 252,000,000 | 245,000,000 |
| Short Term Debt | 499,000,000 | 0 | 500,000,000 |
| Other Liabilities Current | 827,000,000 | 1,325,000,000 | 1,232,000,000 |
| Total Liabilities Current | 1,547,000,000 | 1,570,000,000 | 2,773,000,000 |
| Long Term Debt | 1,989,000,000 | 1,489,000,000 | 0 |
| Other Liabilities Non Current | 339,000,000 | 620,000,000 | 649,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 2,000,000 | 2,000,000 | 2,000,000 |
| Retained Earnings | -1,242,000,000 | -19,000,000 | 1,142,000,000 |
| Accumulated Other Comprehensive Income | 22,000,000 | -1,000,000 | 3,000,000 |
| Total Shareholders Equity | 2,373,000,000 | 5,745,000,000 | 6,599,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 354,000,000 | 432,000,000 | 394,000,000 |
| Share Based Compensation Expense | 370,000,000 | 380,000,000 | 366,000,000 |
| Other Non Cash Income Expense | -14,000,000 | -10,000,000 | -17,000,000 |
| Change In Accounts Receivable | 25,000,000 | 40,000,000 | 12,000,000 |
| Change In Inventories | -19,000,000 | 20,000,000 | 135,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -4,000,000 | -44,000,000 | -38,000,000 |
| Change In Other Liabilities | -440,000,000 | 15,000,000 | 381,000,000 |
| Cash From Operating Activities | 837,000,000 | 478,000,000 | 392,000,000 |
| Purchases Of Marketable Securities | — | 0 | 0 |
| Sales Of Marketable Securities | — | 0 | 0 |
| Acquisition Of Property Plant And Equipment | 128,000,000 | 195,000,000 | 286,000,000 |
| Acquisition Of Business | 81,000,000 | 29,000,000 | 85,000,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -178,000,000 | -231,000,000 | -591,000,000 |
| Tax Withholding For Share Based Compensation | 32,000,000 | 40,000,000 | 54,000,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 56,000,000 | 67,000,000 | 63,000,000 |
| Repurchase Of Common Stock | 116,000,000 | — | 0 |
| Issuance Of Long Term Debt | 1,241,000,000 | 0 | 991,000,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -570,000,000 | -1,210,000,000 | 1,000,000,000 |
| Change In Cash | 79,000,000 | -963,000,000 | 779,000,000 |
| Cash At End Of Period | 1,127,000,000 | 1,048,000,000 | 2,011,000,000 |
| Income Taxes Paid | 105,000,000 | 65,000,000 | 122,000,000 |
| Interest Paid | 83,000,000 | 73,000,000 | 26,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -7.69 | -7.34 | -28 |
| Price To Earnings Ratio | -17.3693 | -18.6259 | -7.0904 |
| Earnings Growth Rate | 4.7684 | -73.7857 | -652.2682 |
| Price Earnings To Growth Ratio | -3.6426 | 0.2524 | 0.0109 |
| Book Value Per Share | 29.9119 | 54.057 | 60.3758 |
| Price To Book Ratio | 4.4654 | 2.5291 | 3.2883 |
| Ebitda | -664,000,000 | -587,000,000 | -3,862,000,000 |
| Enterprise Value | 22,598,630,000 | 22,041,796,200 | 29,658,461,200 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 1.0485 | 0.2592 | 0.0758 |
| Capital Expenditures | 162,000,000 | 348,000,000 | 461,000,000 |
| Free Cash Flow | 675,000,000 | 130,000,000 | -69,000,000 |
| Return On Equity | -0.5154 | -0.2021 | -0.6674 |
| One Year Beta | 1.1656 | 1.4429 | 1.4667 |
| Three Year Beta | 1.4042 | 1.3756 | 1.0729 |
| Five Year Beta | 1.1068 | 1.1128 | 1.1448 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Thaysen Jacob | Director, Chief Executive Officer | 2025-10-05 | 1,301 | D | 82,089 |
| Ullem Scott B. | Director | 2025-09-30 | 252 | A | 8,389 |
| Barnard Steven | SVP, Chief Technology Officer | 2025-09-05 | 287 | D | 33,546 |
| Cunningham Everett | SVP, Chief Commercial Officer | 2025-07-05 | 4,248 | D | 41,942 |
| Ullem Scott B. | Director | 2025-06-30 | 307 | A | 8,137 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Sheldon Whitehouse | Senator | 2020-04-14 | Sale (Full) | 2020-03-11 | Self | $1,001 - $15,000 |
| Sheldon Whitehouse | Senator | 2019-01-10 | Purchase | 2018-12-28 | Self | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-09 | Spouse | $1,001 - $15,000 |
| Thomas H. Kean | 2025-05-15 | NJ07 | Purchase | 2025-04-01 | — | $1,001 - $15,000 |
| Thomas H. Kean | 2025-04-18 | NJ07 | Purchase | 2025-04-01 | — | $1,001 - $15,000 |
| Michael C. Burgess | 2024-10-01 | TX26 | Sale | 2024-08-30 | — | $15,001 - $50,000 |
| Michael C. Burgess | 2024-09-24 | TX26 | Sale | 2024-09-03 | Spouse | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| 180 WEALTH ADVISORS, LLC | 2025-09-30 | 3,343,514 | 35,206 | 94.97 |
| GREENWOOD CAPITAL ASSOCIATES LLC | 2025-09-30 | 369,053 | 3,886 | 94.9699 |
| HALBERT HARGROVE GLOBAL ADVISORS, LLC | 2025-09-30 | 1,425 | 15 | 95 |
| Capital Advisors, Ltd. LLC | 2025-09-30 | 11,000 | 113 | 97.3451 |
| Cohen Klingenstein LLC | 2025-09-30 | 284,910 | 3,000 | 94.97 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| TRUST FOR PROFESSIONAL MANAGERS | 2025-08-31 | Column Mid Cap Fund | CFMCX | 2,883 | 288,184.68 | 0.0289 |
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 554 | 56,901.34 | 0.0238 |
| Pacer Funds Trust | 2025-07-31 | Pacer Trendpilot US Mid Cap ETF | PTMC | 22,464 | 2,307,277.44 | 0.5506 |
| PRIMECAP Odyssey Funds | 2025-07-31 | PRIMECAP Odyssey Stock Fund | POSKX | 51,500 | 5,289,565 | 0.1248 |
| PRIMECAP Odyssey Funds | 2025-07-31 | PRIMECAP Odyssey Growth Fund | POGRX | 30,400 | 3,122,384 | 0.0656 |